It is easy to understand why everyone is desperate for anything that will help with Alzheimer’s Disease. Patients and their families dread its relentless onslaught. Consequently, there was tremendous pressure for the FDA to approve Aduhelm (aducanumab), by Biogen and Eisai. However, it’s approval was met with widespread criticism because it is both expensive, with … Continue reading FDA Approves Expensive Alzheimer’s Drug And Continues To Ignore Cannabis